cefiderocol 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
antibiotics, cefalosporanic acid derivatives 5352 1225208-94-5

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • cefiderocol
  • cefiderocol sulfate tosylate
  • S-649266
  • GSK2696266
  • fetcroja
Cefiderocol is a cephalosporin antibacterial with activity against Gram-negative aerobic bacteria. Cefiderocol functions as a siderophore and binds to extracellular free ferric iron. In addition to passive diffusion via porin channels, cefiderocol is actively transported across the outer cell membrane of bacteria into the periplasmic space using a siderophore iron uptake mechanism. Cefiderocol exerts bactericidal action by inhibiting cell wall biosynthesis through binding to penicillin-binding proteins (PBPs)
  • Molecular weight: 752.21
  • Formula: C30H34ClN7O10S2
  • CLOGP: -3.98
  • LIPINSKI: 3
  • HAC: 17
  • HDO: 6
  • TPSA: 256.90
  • ALOGS: -5.60
  • ROTB: 13

  • Status: ONP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

None

ADMET properties:

PropertyValueReference
S (Water solubility) 100 mg/mL Bocci G, Oprea TI, Benet LZ
BDDCS (Biopharmaceutical Drug Disposition Classification System) 3 Bocci G, Oprea TI, Benet LZ

Approvals:

DateAgencyCompanyOrphan
April 23, 2020 EMA Shionogi B.V.
Nov. 14, 2019 FDA SHIONOGI INC

FDA Adverse Event Reporting System (Female)

None

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

None

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC J01DI04 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIBACTERIALS FOR SYSTEMIC USE
OTHER BETA-LACTAM ANTIBACTERIALS
Other cephalosporins and penems
FDA CS M0003827 Cephalosporins
FDA EPC N0000175488 Cephalosporin Antibacterial
CHEBI has role CHEBI:26672 siderochromes
CHEBI has role CHEBI:36047 antibacterial drugs

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Pyelonephritis indication 45816000 DOID:11400
Urinary tract infectious disease indication 68566005
Escherichia coli urinary tract infection indication 301011002
Proteus urinary tract infection indication 301012009
Pseudomonas urinary tract infection indication 301013004
Bacterial urinary infection indication 312124009
Gram-Negative Bacterial Infections indication 371583007
Urinary tract infection caused by Klebsiella indication




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 2.35 acidic
pKa2 3.44 acidic
pKa3 6.17 acidic
pKa4 9.6 acidic
pKa5 13.61 acidic
pKa6 2.83 Basic

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
EQ 1GM BASE/VIAL FETROJA SHIONOGI INC N209445 Nov. 14, 2019 RX POWDER INTRAVENOUS 9238657 Nov. 14, 2033 METHOD OF TREATING BACTERIAL INFECTIONS
EQ 1GM BASE/VIAL FETROJA SHIONOGI INC N209445 Nov. 14, 2019 RX POWDER INTRAVENOUS 9238657 Nov. 14, 2033 METHOD OF TREATING COMPLICATED URINARY TRACT INFECTIONS (CUTI), INCLUDING PYELONEPHRITIS, COMPRISING ADMINISTERING CEFIDEROCOL SULFATE TOSYLATE
EQ 1GM BASE/VIAL FETROJA SHIONOGI INC N209445 Nov. 14, 2019 RX POWDER INTRAVENOUS 9238657 Nov. 14, 2033 METHOD OF TREATING HOSPITAL-ACQUIRED BACTERIAL PNEUMONIA AND VENTILATOR-ASSOCIATED BACTERIAL PNEUMONIA (HABP/VABP) COMPRISING ADMINISTERING CEFIDEROCOL SULFATE TOSYLATE

Orange Book exclusivity data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRouteExclusivity dateDescription
EQ 1GM BASE/VIAL FETROJA SHIONOGI INC N209445 Nov. 14, 2019 RX POWDER INTRAVENOUS Sept. 25, 2023 INDICATED IN PATIENTS 18 YEARS OF AGE AND OLDER FOR THE TREATMENT OF HOSPITAL ACQUIRED BACTERIAL PNEUMONIA AND VENTILATOR-ASSOCIATED BACTERIAL PNEUMONIA (HABP/VABP) CAUSED BY THE FOLLOWING SUSCEPTIBLE GRAM-NEGATIVE MICROORGANISMS: ACINETOBACTER BAUMANNII COMPLEX, ESCHERICHIA COLI, ENTEROBACTER CLOACAE COMPLEX, KLEBSIELLA PNEUMONIAE, PSEUDOMONAS AERUGINOSA, AND SERRATIA MARCESCENS
EQ 1GM BASE/VIAL FETROJA SHIONOGI INC N209445 Nov. 14, 2019 RX POWDER INTRAVENOUS Nov. 14, 2024 NEW CHEMICAL ENTITY
EQ 1GM BASE/VIAL FETROJA SHIONOGI INC N209445 Nov. 14, 2019 RX POWDER INTRAVENOUS Nov. 14, 2029 GENERATING ANTIBIOTIC INCENTIVES NOW

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Peptidoglycan synthase FtsI Enzyme INHIBITOR IC50 7.40 SCIENTIFIC LITERATURE DRUG LABEL
Penicillin-binding protein 1A Enzyme INHIBITOR IC50 6.07 SCIENTIFIC LITERATURE DRUG LABEL
Penicillin-binding protein 1A Enzyme INHIBITOR IC50 5.48 SCIENTIFIC LITERATURE DRUG LABEL
Penicillin-binding protein 1B Enzyme INHIBITOR IC50 5.47 SCIENTIFIC LITERATURE DRUG LABEL
Penicillin-binding protein 1A Enzyme INHIBITOR IC50 5.98 SCIENTIFIC LITERATURE DRUG LABEL
Penicillin-binding protein 1B Enzyme INHIBITOR IC50 5.46 SCIENTIFIC LITERATURE DRUG LABEL
Peptidoglycan D,D-transpeptidase MrdA Enzyme INHIBITOR IC50 5.66 SCIENTIFIC LITERATURE DRUG LABEL
Peptidoglycan D,D-transpeptidase MrdA Enzyme INHIBITOR IC50 7.20 SCIENTIFIC LITERATURE DRUG LABEL
Peptidoglycan D,D-transpeptidase FtsI Enzyme INHIBITOR IC50 7.21 SCIENTIFIC LITERATURE DRUG LABEL
Peptidoglycan D,D-transpeptidase FtsI Enzyme INHIBITOR IC50 7.22 SCIENTIFIC LITERATURE DRUG LABEL
Peptidoglycan D,D-transpeptidase FtsI Enzyme INHIBITOR IC50 6.17 SCIENTIFIC LITERATURE DRUG LABEL
Penicillin-binding protein 4 Enzyme INHIBITOR IC50 5.44 SCIENTIFIC LITERATURE DRUG LABEL

External reference:

IDSource
SZ34OMG6E8 UNII
2135543-94-9 SECONDARY_CAS_RN
C4548369 UMLSCUI
CHEBI:140376 CHEBI
CHEMBL3989974 ChEMBL_ID
77843966 PUBCHEM_CID
DB14879 DRUGBANK_ID
CHEMBL4297211 ChEMBL_ID
D11302 KEGG_DRUG
10234 INN_ID
10776 IUPHAR_LIGAND_ID
018219 NDDF
018220 NDDF
1217151007 SNOMEDCT_US
830101009 SNOMEDCT_US
830161006 SNOMEDCT_US
4039174 VANDF
2265702 RXNORM
37832 MMSL
d09462 MMSL
C000612166 MESH_SUPPLEMENTAL_RECORD_UI

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Fetroja HUMAN PRESCRIPTION DRUG LABEL 1 59630-266 INJECTION, POWDER, FOR SOLUTION 1 g INTRAVENOUS NDA 31 sections